全球研究显示：印度在Covid-19疫苗预购方面具有优势

根据一项新的全球实验性疫苗市场承诺（advance market commitments，AMCs）全球分析报告: 就已确认剂量而言，以制造业发达闻名的印度在预购疫苗方面展示了购买力，预先订购6亿剂Covid-19疫苗，并正在谈判另外10亿剂疫苗，足以让印度国内至少一半的人口接种疫苗（大多数实验性Covid-19疫苗需要两个剂量）。这一数字仅次于美国，美国已预先订购了8.1亿剂确认剂量，另有16亿剂正在谈判中。

“欧盟已确认4亿剂，正在谈判中的另外15.65亿剂，排名第三。但是，在确认购买的人口中，加拿大已经预先购买了足够的疫苗，足以覆盖527%的人口，英国紧随其后，占其人口的277%，“ 杜克大学全球健康创新中心（Duke Global Health Innovation Center）项目部助理主任Andrea D Taylor说。“当然，最重要的是，很可能只有一部分疫苗可以通过监管部门批准后才能购买。”

但是，如果想要制造足够的疫苗来覆盖全世界的人口，可能需要三到四年的时间。

India has used its manufacturing capability to pre-order 600 million doses of the coronavirus disease (Covid-19) vaccine and is negotiating for another billion doses, enough to vaccinate at least half the population, according to a new global analysis of advance market commitments (AMCs) for experimental vaccines till October 8. Most experimental Covid-19 vaccines require two doses. The figures are second only to the US, which has pre-ordered 810 million confirmed doses and has another 1.6 billion under negotiation.

"The EU (400 million doses confirmed, another 1.565 billion doses under negotiation). But in terms of percent of population covered by confirmed purchases, Canada has pre-purchased enough vaccine to cover 527% of their population, followed by the UK at 277% of their population,” said Andrea D Taylor, assistant director of programmes at the Duke Global Health Innovation Center, who led the analysis. “Of course, it is important to remember that most likely only some of the vaccine purchases will come through, depending on regulatory approval,” said Taylor.

It will likely take three to four years to manufacture enough vaccines to cover the world’s population.   source

指尖新闻：高信噪比，一目了然

新冠疫情追踪